Clinical Investigation of Safety and Effectiveness of Emerald IPLdevice
NCT ID: NCT03945383
Last Updated: 2022-10-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
120 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-04-15
Study Completion Date
2022-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Prospective, multi-center, single-arm, single blinded (Philips hair counter) study in healthy women of skin types I up to and including V.
Safety and efficacy of hair removal with the Emerald IPL-device will be investigated for treatment in face of subjects with ST I - IV and for treatment in face, axilla, bikini area, and legs of subjects with ST V.
In-clinic, the study subjects will undergo twelve IPL-treatments bilaterally at the qualified areas (face and / or axilla, bikini line, and legs) with the Emerald IPL device applied by a device operator.
Hair re-growth in each area will be evaluated separately and across all skin types.
After the 4 bi-weekly treatments, one follow-up visit will be organized two weeks after the 4th treatment. After the completion of the full treatment cycle (12 treatments), subjects will be followed for 1 and 3 months (short-term follow-up) and for 6, 9 and 12 months (long-term follow up).
Safety and efficacy of hair removal with the Emerald IPL-device will be investigated for treatment in face of subjects with ST I - IV and for treatment in face, axilla, bikini area, and legs of subjects with ST V.
In-clinic, the study subjects will undergo twelve IPL-treatments bilaterally at the qualified areas (face and / or axilla, bikini line, and legs) with the Emerald IPL device applied by a device operator.
Hair re-growth in each area will be evaluated separately and across all skin types.
After the 4 bi-weekly treatments, one follow-up visit will be organized two weeks after the 4th treatment. After the completion of the full treatment cycle (12 treatments), subjects will be followed for 1 and 3 months (short-term follow-up) and for 6, 9 and 12 months (long-term follow up).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Hypertrichosis With Intense Pulsed Light
NCT05775328
Hypertrichosis
Hirsutism - Hypertrichosis
RECRUITING
Evaluation of Safety and Efficacy of IPL Presets for Cutaneous Lesions
NCT05630690
Vascular Lesion
Pigmented Lesions
RECRUITING
NA
Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
NCT06655129
Excessive Hairiness
Vascular Lesion
Pigmented Lesions
+1 more
RECRUITING
NA
Laser to Aid in Treatment of Keratosis Pilaris on Arms
NCT05666011
Keratosis Pilaris
UNKNOWN
NA
Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias
NCT02761174
Telangiectasias
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hair grows in cyclic phases: anagen, catagen and telogen. These phases impact on how the process of light-based hair removal works. The hair grows during the anagen phase, which has the longest duration in the hair growth cycle. Hair growth ends with the transition from anagen into the catagen phase, a short transition phase to prepare for the resting phase, the telogen, which ends with shedding of the hair and the start of the hair growth cycle. During telogen phase, the hair follicle remains inactive. Each hair follicle is independent and goes through the growth cycle at different times. As presented in table 5 \[11\], the duration of the growth cycle of the upper lip, axilla and bikini line are different from that of the legs. In general, the telogen and anagen phase's durations of the cycle are longest for the legs (i.e., 24 and 16 weeks, respectively) and the shortest for upper lip (i.e. 6 weeks for both phases). Therefore, hair response to the IPL treatment will be evaluated by body area.
The efficacy of permanent hair reduction will be measured following the definition of permanent hair reduction according to the FDA as follows: "Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs re-growing after a treatment regime, which may include several sessions. The number of hairs re-growing must be stable over time greater than the duration of the complete growth cycle of hair follicles, which varies from four to twelve months according to body location. Permanent hair reduction does not necessarily imply the elimination of all hairs in the treatment area."
In an attempt to promote permanent hair reduction, the aim is to expose all hairs at least once to an IPL flash and therefore treatment will cover the full duration of a hair growth cycle). The longest relevant full hair growth cycle is on the legs (40 weeks, excluding approximately 2 weeks for the catagen phase). Therefore, a treatment duration of 10 months (approximately 38weeks) has been selected: a full IPL treatment cycle consists of 4 initial treatments, once every 2 weeks, followed by 8 maintenance (monthly) treatments, once every 4 weeks. The hair growth cycle on face (upper lip) is the shortest (12 weeks, 6 weeks in anagen, 6 weeks in telogen phases). The initial treatments in 2 weeks interval are expected to be most beneficial for face treatment.
For this study, there are two cohorts for enrollment:
1. Subjects with Skin Type I-IV for treatment of Face only. (N=53)
2. Subjects with Skin Type V for treatment of all body areas: Face, Axilla, Bikini line and leg. (N=19)
The visits are as follows:
Screening Visit: The volunteers are screened to identify subjects who meet all of the inclusion and none of the exclusion criteria. Device settings are selected based on skin tone and comfort evaluation..
Visits 1-4 (TX1-TX4): Four treatments and the collection of safety and efficacy data are scheduled to occur every 2 weeks/ 14 days; Visits 5 (Initial Treatment 2wk Follow-up): Safety and efficacy data are collected 2 weeks/ 14 days after 4th treatment to demonstrate hair removal performance 8 weeks after baseline.
The efficacy of permanent hair reduction will be measured following the definition of permanent hair reduction according to the FDA as follows: "Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs re-growing after a treatment regime, which may include several sessions. The number of hairs re-growing must be stable over time greater than the duration of the complete growth cycle of hair follicles, which varies from four to twelve months according to body location. Permanent hair reduction does not necessarily imply the elimination of all hairs in the treatment area."
In an attempt to promote permanent hair reduction, the aim is to expose all hairs at least once to an IPL flash and therefore treatment will cover the full duration of a hair growth cycle). The longest relevant full hair growth cycle is on the legs (40 weeks, excluding approximately 2 weeks for the catagen phase). Therefore, a treatment duration of 10 months (approximately 38weeks) has been selected: a full IPL treatment cycle consists of 4 initial treatments, once every 2 weeks, followed by 8 maintenance (monthly) treatments, once every 4 weeks. The hair growth cycle on face (upper lip) is the shortest (12 weeks, 6 weeks in anagen, 6 weeks in telogen phases). The initial treatments in 2 weeks interval are expected to be most beneficial for face treatment.
For this study, there are two cohorts for enrollment:
1. Subjects with Skin Type I-IV for treatment of Face only. (N=53)
2. Subjects with Skin Type V for treatment of all body areas: Face, Axilla, Bikini line and leg. (N=19)
The visits are as follows:
Screening Visit: The volunteers are screened to identify subjects who meet all of the inclusion and none of the exclusion criteria. Device settings are selected based on skin tone and comfort evaluation..
Visits 1-4 (TX1-TX4): Four treatments and the collection of safety and efficacy data are scheduled to occur every 2 weeks/ 14 days; Visits 5 (Initial Treatment 2wk Follow-up): Safety and efficacy data are collected 2 weeks/ 14 days after 4th treatment to demonstrate hair removal performance 8 weeks after baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hair Removal
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
All enrolled subjects will be treated with the investigational device
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with IPL device
The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
Group Type
EXPERIMENTAL
Treatment with IPL device
Intervention Type
DEVICE
Treatment with IPL device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment with IPL device
Treatment with IPL device
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be willing to provide informed consent
2. Are healthy female subjects, in age of 18-65 years
3. Have natural body hair color that is dark blonde, brown or black in the designated treatment areas
3.1. Subjects of ST I-IV - Face group:
3.1.1 Have Fitzpatrick Skin Type I, II, III, or IV
3.1.2 Measure melanin value ≤ 375 in the qualifying treatment areas bilateral on upper lip (face)
3.1.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection
3.2. Subjects of ST V - All body area group:
3.2.1. Have Fitzpatrick Skin Type V
3.2.2. Measure melanin value ≤ 553 in the qualifying treatment areas bilateral on upper lip (face), axilla, bikini line, and leg
3.2.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection
3.2.4.Have a minimum of 24 hairs in each of the 2x4cm2 qualifying treatment areas bilateral on axilla, bikini line, and leg, by visual inspection
4. Be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control (e.g., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence, etc.).
5. Be willing to participate in all study visits
6. Be willing to refrain from deliberate exposure to strong sun, products or procedures that would cause the skin to become darker in the designated treatment areas during the treatment phase
7. Be willing to refrain from the use of hair growth inhibitors/accelerators during the course of the study
8. Be willing to refrain from waxing, depilating or epilating of the axilla, bikini line, leg, and face
9. Be willing to refrain from using aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) within 5 days prior to and 5 days after treatment(s) -
2. Are healthy female subjects, in age of 18-65 years
3. Have natural body hair color that is dark blonde, brown or black in the designated treatment areas
3.1. Subjects of ST I-IV - Face group:
3.1.1 Have Fitzpatrick Skin Type I, II, III, or IV
3.1.2 Measure melanin value ≤ 375 in the qualifying treatment areas bilateral on upper lip (face)
3.1.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection
3.2. Subjects of ST V - All body area group:
3.2.1. Have Fitzpatrick Skin Type V
3.2.2. Measure melanin value ≤ 553 in the qualifying treatment areas bilateral on upper lip (face), axilla, bikini line, and leg
3.2.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection
3.2.4.Have a minimum of 24 hairs in each of the 2x4cm2 qualifying treatment areas bilateral on axilla, bikini line, and leg, by visual inspection
4. Be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control (e.g., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence, etc.).
5. Be willing to participate in all study visits
6. Be willing to refrain from deliberate exposure to strong sun, products or procedures that would cause the skin to become darker in the designated treatment areas during the treatment phase
7. Be willing to refrain from the use of hair growth inhibitors/accelerators during the course of the study
8. Be willing to refrain from waxing, depilating or epilating of the axilla, bikini line, leg, and face
9. Be willing to refrain from using aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) within 5 days prior to and 5 days after treatment(s) -
Exclusion Criteria
1. Have natural body hair color that is white, light blond, or red in the designated treatment areas
1.1. Subjects of ST I to IV - Face group:
1.1.1. Have Fitzpatrick Skin Type V or VI
1.1.2. Measure melanin value higher than 375 in the qualifying treatment areas bilateral on upper lip
1.1.3. Have fewer than 2 qualifying treatment areas on bilateral on upper lip (face)
1.2. Subjects of ST V - All body area group:
1.2.1. Have Fitzpatrick Skin Type I, II, III, IV, or VI
1.2.2. Measure melanin value higher than 553 in any of the qualifying treatment areas bilateral on the body
1.2.3. Have fewer than 8 qualifying treatment areas bilateral: 2 in face, 2 in axilla, 2 on bikini line, and 2 on legs
2. Have a malignant or pre-malignant pigment in the area to be treated
3. Have scarring or infection of the area to be treated
4. Have a known history of photosensitivity or use of medication known to induce photosensitivity
5. Are currently pregnant or lactating or planning be become pregnant in the period of the study, per subject report
6. Are currently on a daily dose of aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) or have taken aspirin and/or NSAIDs within 5 days prior to treatment that would reduce or increase the sensation of pain
7. Are not willing to abstain from the use of products or light exposure that would induce tanning in the treatment areas during the IPL treatment period (first 10 months)
8. Have a history of immunosuppressive disease (including HIV infection or AIDS)
9. Are on a anticoagulative medication or thromboembolic condition
10. Have taken any form of isotretinoin (such as Accutane or Roaccutane etc.) in the last six months
11. Have an active implantable device such as a pacemaker, neurostimulator or internal defibrillator
12. Have used waxing or other methods of root hair removal, or photo-epilation in the areas to be treated within 6 months prior to treatment
13. Have been exposed to strong sunlight or an artificial tanning machine in the area to be treated within 4 weeks of enrolment
14. Have a tattoo(s), warts, moles, benign skin lesions, dark pigmented areas, permanent make-up etc. in the areas to be treated.
15. Have eczema, psoriasis, lesions, open wounds or any skin affliction in the areas to be treated
16. Have a history of keloid scar formation
17. Have a history of herpes outbreaks in the areas to be treated
18. Have a history of photosensitive epilepsy
19. Have a condition related to hormonal changes like polycystic ovarian syndrome (PCOS) or taking drugs leading to hormonal changes resulting in excessive hair growth like hirsutism or idiopathic hirsutism
20. Have diabetes, or metabolic disease that affects hair growth
21. Taking immunosuppressive medication(s)
22. Have a disease related to photosensitivity, such as polymorphic light eruption (PMLE), solar urticaria, porphyria etc.
23. Have a history of skin cancer, including past basal cell carcinoma and/or squamous cell carcinoma in the areas to be treated
24. Have a history of any radiation therapy in any of the areas to be treated
25. Have history of radiation therapy in non-treatment areas within 5 years
26. Have a history of chemotherapy
27. Have used hair growth inhibitors and/or accelerators within 6 months preceding enrolment
28. Have had laser or electrolysis treatment for the removal of hair in the areas to be treated within the last year
29. Have natural body hair colors of white, grey, light to mid-blond, or red in the areas to be treated
30. Have bleaching of their body hair in the areas to be treated 6 months prior to study enrolment
31. Have shaved the areas to be treated within 7 days prior to study enrolment
32. Participating in other clinical studies prior to, or concurrently with this study, that could be deemed to interfere with full and complete participation in this study - as determined by the site investigator.
1.1. Subjects of ST I to IV - Face group:
1.1.1. Have Fitzpatrick Skin Type V or VI
1.1.2. Measure melanin value higher than 375 in the qualifying treatment areas bilateral on upper lip
1.1.3. Have fewer than 2 qualifying treatment areas on bilateral on upper lip (face)
1.2. Subjects of ST V - All body area group:
1.2.1. Have Fitzpatrick Skin Type I, II, III, IV, or VI
1.2.2. Measure melanin value higher than 553 in any of the qualifying treatment areas bilateral on the body
1.2.3. Have fewer than 8 qualifying treatment areas bilateral: 2 in face, 2 in axilla, 2 on bikini line, and 2 on legs
2. Have a malignant or pre-malignant pigment in the area to be treated
3. Have scarring or infection of the area to be treated
4. Have a known history of photosensitivity or use of medication known to induce photosensitivity
5. Are currently pregnant or lactating or planning be become pregnant in the period of the study, per subject report
6. Are currently on a daily dose of aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) or have taken aspirin and/or NSAIDs within 5 days prior to treatment that would reduce or increase the sensation of pain
7. Are not willing to abstain from the use of products or light exposure that would induce tanning in the treatment areas during the IPL treatment period (first 10 months)
8. Have a history of immunosuppressive disease (including HIV infection or AIDS)
9. Are on a anticoagulative medication or thromboembolic condition
10. Have taken any form of isotretinoin (such as Accutane or Roaccutane etc.) in the last six months
11. Have an active implantable device such as a pacemaker, neurostimulator or internal defibrillator
12. Have used waxing or other methods of root hair removal, or photo-epilation in the areas to be treated within 6 months prior to treatment
13. Have been exposed to strong sunlight or an artificial tanning machine in the area to be treated within 4 weeks of enrolment
14. Have a tattoo(s), warts, moles, benign skin lesions, dark pigmented areas, permanent make-up etc. in the areas to be treated.
15. Have eczema, psoriasis, lesions, open wounds or any skin affliction in the areas to be treated
16. Have a history of keloid scar formation
17. Have a history of herpes outbreaks in the areas to be treated
18. Have a history of photosensitive epilepsy
19. Have a condition related to hormonal changes like polycystic ovarian syndrome (PCOS) or taking drugs leading to hormonal changes resulting in excessive hair growth like hirsutism or idiopathic hirsutism
20. Have diabetes, or metabolic disease that affects hair growth
21. Taking immunosuppressive medication(s)
22. Have a disease related to photosensitivity, such as polymorphic light eruption (PMLE), solar urticaria, porphyria etc.
23. Have a history of skin cancer, including past basal cell carcinoma and/or squamous cell carcinoma in the areas to be treated
24. Have a history of any radiation therapy in any of the areas to be treated
25. Have history of radiation therapy in non-treatment areas within 5 years
26. Have a history of chemotherapy
27. Have used hair growth inhibitors and/or accelerators within 6 months preceding enrolment
28. Have had laser or electrolysis treatment for the removal of hair in the areas to be treated within the last year
29. Have natural body hair colors of white, grey, light to mid-blond, or red in the areas to be treated
30. Have bleaching of their body hair in the areas to be treated 6 months prior to study enrolment
31. Have shaved the areas to be treated within 7 days prior to study enrolment
32. Participating in other clinical studies prior to, or concurrently with this study, that could be deemed to interfere with full and complete participation in this study - as determined by the site investigator.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philips Healthcare
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rupal Trivedi, M.D.
Role: PRINCIPAL_INVESTIGATOR
Great Lakes Clinical Trials
David Pariser, M.D.
Role: PRINCIPAL_INVESTIGATOR
Virginia Clinical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
My Community Research Center
Miami, Florida, United States
Site Status
Great Lakes Clinical Trials
Chicago, Illinois, United States
Site Status
Virginia Clinical Research
Norfolk, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Altshuler GB, Anderson RR, Manstein D, Zenzie HH, Smirnov MZ. Extended theory of selective photothermolysis. Lasers Surg Med. 2001;29(5):416-32. doi: 10.1002/lsm.1136.
Reference Type
BACKGROUND
Ravnbak MH. Objective determination of Fitzpatrick skin type. Dan Med Bull. 2010 Aug;57(8):B4153.
Reference Type
BACKGROUND
Shamsuddin K et. al, The reliability of Fitzpatrick Skin Type Chart Comparing to Mexameter (Mx 18) in measuring skin color among first trimester, Malaysian Journal of Public Health Medicine 2016, Vol. 16 (3): 59-65
Reference Type
BACKGROUND
Gold MH, Bell MW, Foster TD, Street S. Long-term epilation using the EpiLight broad band, intense pulsed light hair removal system. Dermatol Surg. 1997 Oct;23(10):909-13. doi: 10.1111/j.1524-4725.1997.tb00746.x.
Reference Type
BACKGROUND
Gold MH, Bell MW, Foster TD, Street S. One-year follow-up using an intense pulsed light source for long-term hair removal. J Cutan Laser Ther. 1999 Sep;1(3):167-71. doi: 10.1080/14628839950516823.
Reference Type
BACKGROUND
Dierickx CC. Hair removal by lasers and intense pulsed light sources. Dermatol Clin. 2002 Jan;20(1):135-46. doi: 10.1016/s0733-8635(03)00052-4.
Reference Type
BACKGROUND
Thaysen-Petersen D, Bjerring P, Dierickx C, Nash JF, Town G, Haedersdal M. A systematic review of light-based home-use devices for hair removal and considerations on human safety. J Eur Acad Dermatol Venereol. 2012 May;26(5):545-53. doi: 10.1111/j.1468-3083.2011.04353.x. Epub 2011 Nov 30.
Reference Type
BACKGROUND
Town G, Ash C, Dierickx C, Fritz K, Bjerring P, Haedersdal M. Guidelines on the safety of light-based home-use hair removal devices from the European Society for Laser Dermatology. J Eur Acad Dermatol Venereol. 2012 Jul;26(7):799-811. doi: 10.1111/j.1468-3083.2011.04406.x. Epub 2012 Jan 3.
Reference Type
BACKGROUND
Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988 Jun;124(6):869-71. doi: 10.1001/archderm.124.6.869. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PC-BEA-Emerald STV&Face-10560
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser
NCT03054155
COMPLETED
NA
To Comapre The Effectiveness of Two Lasers in The Treamment of Unwanted Hair
NCT05739799
COMPLETED
NA
Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa
NCT03203122
UNKNOWN
NA
CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS
NCT07239726
NOT_YET_RECRUITING
NA
Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars
NCT04807179
ACTIVE_NOT_RECRUITING
NA
Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities
NCT05359419
UNKNOWN
PHASE4
Impact of the M22-IPL Acne Filter on Acne Vulgaris
NCT02180282
TERMINATED
NA
Evaluation of Eflornithine on Facial and Forearm Skin
NCT00152048
COMPLETED
PHASE4
Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae
NCT02452359
TERMINATED
NA
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
NCT05060237
COMPLETED
PHASE1
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
NCT03846531
COMPLETED
NA
The Efficacy of 308nm Excimer Laser in White Striae
NCT00361361
COMPLETED
PHASE1
Striae Distensae Treatment Using Deep Skin Abrasion
NCT07087405
NOT_YET_RECRUITING
NA
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
NCT06745999
RECRUITING
PHASE4
Investigating the Safety and Efficacy of the 1927-nm Thulium Laser in Keratosis Pilaris
NCT07078461
RECRUITING
NA
Treatment of Sebaceous Hyperplasia With PDL and Nd:YAG Versus Erbium:YAG: A Randomized Controlled Trial
NCT04429607
NOT_YET_RECRUITING
PHASE2
Pilot Evaluation of Thulium Laser Alone or in Combination With Broad Band Light for Treatment of Dermatologic Conditions
NCT03944278
COMPLETED
NA
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
NCT05662202
ACTIVE_NOT_RECRUITING
PHASE3
Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation
NCT06149780
RECRUITING
NA
Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone
NCT03639857
TERMINATED
NA
Efficacy of Combined 1927nm Thulium Fiber Laser and Supramolecular Salicylic Acid in Photoaging Treatment
NCT06925035
COMPLETED
NA
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
NCT03565341
COMPLETED
NA
Effectivity and Safety of Combination of Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate
NCT05186246
UNKNOWN
PHASE1